Published in Antiviral Res on December 22, 2015
Genome editing and the next generation of antiviral therapy. Hum Genet (2016) 0.88
In vivo disruption of latent HSV by designer endonuclease therapy. JCI Insight (2016) 0.83
CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology (2016) 0.82
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther (2016) 0.80
Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS (2016) 0.80
Attitudes and Willingness to Assume Risk of Experimental Therapy to Eradicate Genital Herpes Simplex Virus Infection. Sex Transm Dis (2016) 0.75
Disruption or Excision of Provirus as an Approach to HIV Cure. AIDS Patient Care STDS (2016) 0.75
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
Stem cell transplantation in strategies for curing HIV/AIDS. AIDS Res Ther (2016) 0.75
Novel AIDS therapies based on gene editing. Cell Mol Life Sci (2017) 0.75
Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases. J Antimicrob Chemother (2016) 0.75
Excision of Latent HIV-1 from Infected Cells In Vivo: An Important Step Forward. Mol Ther (2017) 0.75
The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther (2017) 0.75
In vivo dynamics of AAV-mediated gene delivery to sensory neurons of the trigeminal ganglia. Sci Rep (2017) 0.75
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology (2014) 3.14
HIV-1 proviral DNA excision using an evolved recombinase. Science (2007) 2.81
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol (1998) 2.50
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol (1994) 2.18
HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog (2006) 1.67
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS (2014) 1.59
Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res (2013) 1.48
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med (2015) 1.30
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther (2013) 1.26
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol (2014) 1.26
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One (2011) 1.21
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther (2015) 1.17
CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J Gen Virol (2014) 1.12
Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells. Mol Ther (2011) 1.11
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther (2013) 1.10
Targeted gene disruption to cure HIV. Curr Opin HIV AIDS (2013) 1.09
Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol (2013) 1.05
AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS One (2014) 1.04
In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Commun (2014) 1.04
In vitro Inactivation of Latent HSV by Targeted Mutagenesis Using an HSV-specific Homing Endonuclease. Mol Ther Nucleic Acids (2014) 1.03
Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A (2015) 1.03
A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One (2015) 1.01
Ty3 reverse transcriptase complexed with an RNA-DNA hybrid shows structural and functional asymmetry. Nat Struct Mol Biol (2014) 1.00
Homing endonucleases: DNA scissors on a mission. Genome (2012) 0.94
Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods Enzymol (2014) 0.93
Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol (2014) 0.93
Development of nuclease-mediated site-specific genome modification. Curr Opin Immunol (2012) 0.92
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
Gene- and protein-delivered zinc finger-staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus. PLoS One (2013) 0.87
Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int (2014) 0.87
DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. Virology (2014) 0.86
A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia (2013) 0.85
Retracted Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells. Onco Targets Ther (2014) 0.84
TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest (2014) 0.83
Gene transfer of integration defective anti-HSV-1 meganuclease to human corneas ex vivo. Gene Ther (2014) 0.83
Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells. Clin Cancer Res (2014) 0.81
Engineering designer nucleases with customized cleavage specificities. Curr Protoc Mol Biol (2011) 0.80
Universal Tre (uTre) recombinase specifically targets the majority of HIV-1 isolates. J Int AIDS Soc (2014) 0.79
Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells. Mol Biol Rep (2014) 0.79
Inhibition of DNA replication of human papillomavirus by using zinc finger-single-chain FokI dimer hybrid. Mol Biotechnol (2014) 0.78
Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants. Intervirology (2014) 0.77